Hebei Changshan - Public Comps and Valuation Multiples

Hebei Changshan Overview

About Hebei Changshan

Hebei Changshan Biochemical Pharmaceutical Co Ltd is a biotech high-tech enterprise. It is mainly engaged in the research, development, production, and sale of heparin series products. Some of the company's products are Reserpine sodium, Hyaluronic acid, Heparinoid, Heparin sodium, Tinzaparin sodium, Aspirin enteric-coated tablets, and Yihaitang.

Founded

2000

HQ

Employees

n/a

Website

hbcsbio.com

Sectors

Biopharmaceuticals
BioTech

Financials

Last FY Revenue $146M

Last FY EBITDA -$11.4M

EV

$8.8B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Hebei Changshan Financials

See Hebei Changshan valuation multiples based on analyst estimates

Hebei Changshan P&L

In the most recent fiscal year, Hebei Changshan reported revenue of $146M and EBITDA of -$11.4M.

Hebei Changshan expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Hebei Changshan valuation multiples based on analyst estimates

	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	XXX	$146M	XXX	XXX	XXX
Gross Profit	XXX	$23.5M	XXX	XXX	XXX
Gross Margin	XXX	16%	XXX	XXX	XXX
EBITDA	XXX	-$11.4M	XXX	XXX	XXX
EBITDA Margin	XXX	-8%	XXX	XXX	XXX
EBIT	XXX	-$13.7M	XXX	XXX	XXX
EBIT Margin	XXX	-9%	XXX	XXX	XXX
Net Profit	XXX	-$35.3M	XXX	XXX	XXX
Net Margin	XXX	-24%	XXX	XXX	XXX
Net Debt	XXX	$185M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Hebei Changshan including revenue, profitability, and margin analysis across different time periods. In the most recent fiscal year, Hebei Changshan achieved $146M in revenue and -$11.4M in EBITDA.
Financial Metric	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	Analyst estimates available to subscribers	$146M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	Analyst estimates available to subscribers	$23.5M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	Analyst estimates available to subscribers	16.1% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	Analyst estimates available to subscribers	-$11.4M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	Analyst estimates available to subscribers	-7.8% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	Analyst estimates available to subscribers	-$13.7M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	Analyst estimates available to subscribers	-9.4% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	Analyst estimates available to subscribers	-$35.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	Analyst estimates available to subscribers	-24.2% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	$185M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Hebei Changshan

This financial data table provides comprehensive performance metrics for Hebei Changshan, a company based in China. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Fiscal Year Performance

In the most recent fiscal year, Hebei Changshan reported $146M in total revenue.
Fiscal year EBITDA was -$11.4M.
The company maintained a gross profit margin of 16.1% in the most recent fiscal year.
EBITDA margin for the fiscal year was -7.8%.
Net profit margin reached -24.2% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Hebei Changshan. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Hebei Changshan Stock Performance

Hebei Changshan has current market cap of CNY 60.2B (or $8.5B), and EV of CNY 62.4B (or $8.8B).

Market Cap Evolution

Hebei Changshan Stock Data

As of December 4, 2025, Hebei Changshan's stock price is CNY 65 (or $9).

See Hebei Changshan trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$8.8B	$8.5B	XXX	XXX	XXX	XXX	n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Hebei Changshan Valuation Multiples

Hebei Changshan's trades at 60.6x EV/Revenue multiple, and -775.2x EV/EBITDA.

See valuation multiples for Hebei Changshan and 15K+ public comps

Hebei Changshan Financial Valuation Multiples

As of December 4, 2025, Hebei Changshan has market cap of $8.5B and EV of $8.8B.

Equity research analysts estimate Hebei Changshan's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Hebei Changshan's P/E ratio is not available.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$8.5B	XXX	$8.5B	XXX	XXX	XXX
EV (current)	$8.8B	XXX	$8.8B	XXX	XXX	XXX
EV/Revenue	n/a	XXX	60.6x	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	-775.2x	XXX	XXX	XXX
EV/EBIT	n/a	XXX	-646.3x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	n/a	XXX	-241.2x	XXX	XXX	XXX
EV/FCF	n/a	XXX	-340.5x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Hebei Changshan Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Hebei Changshan Margins & Growth Rates

Hebei Changshan's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

Hebei Changshan's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Hebei Changshan's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Hebei Changshan and other 15K+ public comps

Hebei Changshan Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	-8%	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	n/a	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	6%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	5%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	25%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial